This site is intended for U.S. Healthcare Professionals only.

  • U.S. Full Prescribing Information |
  • Medication Guide |
  • Indication


    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

A first-line oral option for
adults with moderate-to-severe
plaque psoriasis1

*POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis. See additional study design details.1

Co-primary endpoints: percentage of patients achieving PASI 75 at Week 16 vs placebo and percentage of patients achieving sPGA 0/1 vs placebo at Week 16. The results were achieved for PASI 75 (POETYK PSO-1: 58% vs 13%; POETYK PSO-2: 53% vs 9%) and sPGA 0/1 (POETYK PSO-1: 54% vs 7%; POETYK PSO-2: 50% vs 9%). Statistical significance was achieved for secondary endpoint PASI 75 vs apremilast at Week 16 (POETYK PSO-1: 58% vs 35%; POETYK PSO-2: 53% vs 40%).1

PASI=psoriasis area and severity index; PASI 75=75% reduction from baseline in PASI; sPGA 0/1=statistic Physician’s Global Assessment, patients achieving clear (0) or almost clear (1) skin.

SOTYKTU tablet is not actual size. Shown for illustrative purposes only.

Bristol Myers Squibb™ Logo

are trademarks of Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc.

© 2023 Bristol-Myers Squibb Company.

1787-US-2300483 07/23

1787-US-2300303 06/23

1787-US-2300737 10/23

1787-US-2300483 07/23

1787-US-2300303 06/23